Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou(Shanghai Pulmonary Hospital), Chongyang Li(Shanghai Medical College of Fudan University), Libo Luo(Tongji University), Xin Li(Jiangsu Hengrui Medicine (China)), Keyi Jia(Tongji University), Ning He(Jiangsu Hengrui Medicine (China)), Shiqi Mao(Tongji University), Wanying Wang(Tongji University), Chuchu Shao(Tongji University), Xinyu Liu(Tongji University), Kan Huang(Fudan University Shanghai Cancer Center), Yaxin Yu(Shanghai Medical College of Fudan University), Xinlei Cai(Westlake University), Yingxue Chen(Shanghai Medical College of Fudan University), Zican Dai(Shanghai Medical College of Fudan University), Wei Li(Tongji University), Jia Yu(Tongji University), Jiayu Li(Tongji University), Feng Shen(Jiangsu Hengrui Medicine (China)), Zaiyong Wang(Jiangsu Hengrui Medicine (China)), Feng He(Jiangsu Hengrui Medicine (China)), Xing Sun(Jiangsu Hengrui Medicine (China)), Rongfu Mao(Jiangsu Hengrui Medicine (China)), Wei Shi(Jiangsu Hengrui Medicine (China)), Jun Zhang(The University of Kansas Cancer Center), Tao Jiang(Shanghai Pulmonary Hospital), Zhe Zhang(Jiangsu Hengrui Medicine (China)), Fei Li(Fudan University), Shengxiang Ren(Tongji University)
Cited by 78